Seminars in Radiation Oncology
Volume 19, Issue 1 , Pages 29-34 , January 2009

Strategies for Managing Radiation-Induced Mucositis in Head and Neck Cancer

  • David I. Rosenthal, MD

      Affiliations

    • The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationAddress reprint requests to David I. Rosenthal, MD, Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Unit 97 1515 Holcombe Blvd, Houston TX 77030
    • ,
  • Andrea Trotti, MD

      Affiliations

    • H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL

References 

  1. Sonis T, Peterson DE, McGuire DB, et al. Prevention of mucositis in cancer patients. J Natl Cancer Inst Monogr. 2001;(29):1–2
  2. Rosenthal C, Karthaus M, Ganser A. New strategies in the treatment and prophylaxis of chemo- and radiotherapy-induced oral mucositis. Antibiot Chemother. 2000;50:115–132
  3. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol. 2006;24:2636–2643
  4. Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: The development and validation of the M.D. Anderson symptom inventory, head and neck module. Head Neck. 2007;29:923–931
  5. Rosenthal DI, Mendoza TR, Chambers MS, et al. The M.D. Anderson symptom inventory–head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys. 2008;May 21; [Epub ahead of print]
  6. Jones HA, Hershock D, Machtay M, et al. Preliminary investigation of symptom distress in the head and neck patient population: Validation of a measurement instrument. Am J Clin Oncol. 2006;29:158–162
  7. Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: A follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys. 1994;28:847–856
  8. Cooper JS, Fu K, Marks J, et al. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys. 1995;31:1141–1164
  9. Harrison LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck. 1997;19:169–175
  10. Epstein JB, Gorsky M, Guglietta A, et al. The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer. 2000;89:2258–2265
  11. Kagami H, Hiramatsu Y, Hishida S, et al. Salivary growth factors in health and disease. Adv Dent Res. 2000;14:99–102
  12. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res. 1987;66:648–653
  13. Sonis ST. Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?. Nat Clin Pract Oncol. 2005;2:134–135
  14. Blijlevens NM. Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol. 2005;17:605–610
  15. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–284
  16. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report (Prevention and management of mucositis in cancer care). J Natl Compr Canc Netw. 2008;6(suppl 1):S1–S21
  17. Quinn B, Potting CM, Stone R, et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer. 2008;44:61–72
  18. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–831
  19. Worthington HV, Clarkson JE. Eden OB: Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;4:CD000978
  20. Garden AS, Asper JA, Morrison WH, et al. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma?. Cancer. 2004;100:1171–1178
  21. Garden AS, Morrison WH, Wong PF, et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:438–444
  22. Rosenthal DI, Blanco AI. Head and neck squamous cell carcinoma: Optimizing the therapeutic index. Expert Rev Anticancer Ther. 2005;5:501–514
  23. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98
  24. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  25. National Cancer Institute: Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ). http://www.cancer.gov/cancer topics/pdg/supportivecare/oralcomplicationsAccessed Oct. 9, 2008
  26. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025
  27. Marx RE, Johnson RP. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol. 1987;64:379–390
  28. Rosenthal DI, Chambers MS, Fuller CD, et al. Beam path toxicities to non-target structures during intensity modualted radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2008;72:747–755
  29. McGuire DB, Correa ME, Johnson J, et al. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006;14:541–547
  30. Barasch A, Spijkervet A, Garden A, et al. Efficacy of opioid analgesics and effect on functional status of pain caused by radiation-induced mucositis among patients with head and neck cancer. J Clin Oncol. 2008;26:abstr 6019
  31. Eisbruch A, Levendag PC, Feng FY, et al. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? (The Michigan and Rotterdam experiences). Int J Radiat Oncol Biol Phys. 2007;69:S40–S42
  32. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys. 2007;68:1289–1298
  33. Chao KS, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques. Radiother Oncol. 2001;61:275–280
  34. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345
  35. Chambers MS, Welsh DV, Scrimger RA, et al. RK-0202 for radiation-induced oral mucositis. J Clin Oncol. 2006;24:5523
  36. Ryu JK, Swann S, LeVeque F, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: A double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys. 2007;67:643–650
  37. Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, et al. A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: A preliminary report. Int J Radiat Oncol Biol Phys. 1998;42:551–556
  38. Rovirosa A, Ferre J, Biete A. Granulocyte macrophage-colony-stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:747–754
  39. Sprinzl GM, Galvan O, de Vries A, et al. Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer. 2001;37:2003–2009
  40. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161–1171
  41. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  42. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol. 2006;24:4708–4713
  43. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598
  44. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol. 2008;26:2489–2496
  45. Antunes HS, de Azevedo AM, da Silva Bouzas LF, et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: A randomized trial. Blood. 2007;109:2250–2255
  46. Schubert MM, Eduardo FP, Guthrie KA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer. 2007;15:1145–1154
  47. Foote RL, Loprinzi CL, Frank AR, et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol. 1994;12:2630–2633
  48. Symonds RP, McIlroy P, Khorrami J, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: A placebo-controlled double-blind trial. Br J Cancer. 1996;74:312–317
  49. Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004;58:674–681
  50. Leborgne JH, Leborgne F, Zubizarreta E, et al. Corticosteroids and radiation mucositis in head and neck cancer (A double-blind placebo-controlled randomized trial). Radiother Oncol. 1998;47:145–148
  51. Hanson WR, Marks JE, Reddy SP, et al. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Adv Exp Med Biol. 1997;400B:811–818
  52. Porteder H, Rausch E, Kment G, et al. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg. 1988;16:371–374
  53. Labar B, Mrsic M, Pavletic Z, et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant. 1993;11:379–382
  54. Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: A randomized double-blind study. Bone Marrow Transplant. 1996;17:809–812
  55. Lalla RV, Schubert MM, Bensadoun RJ, et al. Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer. 2006;14:558–565
  56. Epstein JB, Silverman S, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer. 2001;92:875–885
  57. Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol. 1986;62:145–148

PII: S1053-4296(08)00061-1

doi: 10.1016/j.semradonc.2008.09.006

Seminars in Radiation Oncology
Volume 19, Issue 1 , Pages 29-34 , January 2009

Article Tools